1. No category

Harald H.H.W. Schmidt, MD PhD PharmD
Executive Statement:
Harald Schmidt, MD PhD PharmD, completed studies in both Pharmacy and Medicine and is
currently at Maastricht University, Netherlands, as Professor and Chair of Pharmacology and
Personalised Medicine, PI and Member of Board of the inter-faculty Institute for Advanced Studies,
PI of the Cardiovascular Research Institute, and co-leader of his Faculty’s Innovation Platform.
Harald Schmidt has previously worked in Australia, Germany and USA in different academic
and business leadership positions. These included Associate Dean and member of the University’s
Equity Committee co-initiating a Women in Science programme, Monash University (Australia);
member of Senate at University of Würzburg (Germany) and Monash University; Faculty Board
(Gießen); director of interfaculty research Centre for Vascular Health (Monash); co-leader of two
SFPs and member of promotion commission (Gießen); member of different higher education
political advisory groups (Victoria, Australia and NRW).
With respect to teaching, Harald Schmidt edited a leading Pharmacology & Toxicology
textbook, initiated and led didactic courses for university lecturers, co-led the pre-clinical curriculum
commission (Monash) and developed novel and innovative courses including problem-based and
online learning (Würzburg and Maastricht); interdisciplinary summer schools together with the Law
and Economics faculty.
Scientifically, Harald Schmidt has published close to 200 peer-reviewed papers and reviews
(including Cell, Science, Nature Cell Biology, Nature Reviews Drug Discovery, Proc. Natl. Acad.
Sci. U.S.A.; h-index=73), 3 books and 14 patents. He worked several years with the later Nobel
Laureate, Ferid Murad (USA), and has been awarded a European Research Council Advanced
Investigator programme, founded a European Science Foundation COST action, and co-leads an
FP7 EUROSTAR programme.
With respect to valorisation, Harald Schmidt founded both a drug discovery CRO at TransMIT
GmbH (Gießen) and co-founded, financed and, for two years, led as CEO Vasopharm GmbH, a
successful drug discovery company now entering into phase III clinical development. He has
leadership functions in learned societies, editorial roles and was awarded the Roche Research
Prize for Cell Biology, the Phoenix Research Prize in Pharmacy, and the Pro Scientia Prize.
1.
Personal details:
Full Name:
Home address:
E-mail:
Tel.:
Date and place of birth:
Nationality:
Gender:
Marital status:
2.
Professional address:
Name university / institute:
Department:
Postal address:
Tel.:
Fax:
E-mail:
3.
Harald Horst Heinz Wilhelm Schmidt
Elsa-Brändström-Straße 7
52070 Aachen, Germany
[email protected]
+49 241 40006862
1 February 1959, Kassel, Germany
German
Male
Married, 2 children (20 and 22)
Maastricht University / CARIM & MIAS
Dept. of Pharmacology, Prof of Pharmacology and Drug Discovery
P.O. Box 616, 6200 MD Maastricht
+31 43 388 1421 / +31 6 46705510 (mobile)
+31 43 388 4149
[email protected]
Training / Education (including graduation)
Academic:
CV – Harald HHW Schmidt, MD PhD PharmD !
!
!
!
1983: B. Pharm. Sci. (Pharmaceutical degree), University of Munich, Germany
1987: MBBS (Medical degree), Free University of Berlin, Germany
1987: Dr. med. (PhD in Medicine), University of Freiburg, Germany
1995: Dr. med. habil. (Habilitation), University of Würzburg, Germany
Vocational:
! 1983: Registered Pharmacist (Germany, valid in EU)
! 1987: Medical Registration (Germany, valid in EU; temporary in Australia)
! 1994: Medical Specialisation in ‘Pharmacology and Toxicology’ (Germany)
! 1996: Pharmaceutical Specialisation in ‘Pharmaceutical Analytics’ (Germany)
Professional Development:
! 1998: Rhetoric course, Weihenstephan
! 2002: Schmidt-Colleg Leadership training, Mini MBA
! 2006: Senior Leadership Course, Monash University
! 2007: Rhetoric and staff management course, Stuttgart
! 2008: Finance for Non-Financial Managers, Australian Institute for Management
! 2013: Power of Negotiation, Harvard University
4.
Professional appointments
2010-ongoing
2009
2007-2009
2005-2009
2000-20 05
1996-1999
1992-1996
1990-1992
1989-1990
1987-1989
1986
5.
Professor of Pharmacology and Personalised Medicine, Maastricht University, The
Netherlands
Associate Dean International Research, Faculty of Medicine, Nursing and Health
Sciences
Director, Centre for Vascular Health, Monash University, Australia
Professor and Head, Department or Pharmacology, Monash University, Australia
Professor and Head of the Rudolf-Buchheim-Institute for Pharmacology, JustusLiebig-University, Gießen, Germany
Professor of Pharmacology and Toxicology, University of Würzburg, Germany
CEO of Vasopharm GmbH, Würzburg, Germany
Principal Research Fellow equivalent, Department of Medicine, Clinical Research
Group, University Clinics, Würzburg, Germany
Adjunct Assistant Professor, Northwestern University Medical School, Department
of Pharmacology, Chicago, USA
Senior Research Scientist, Abbott Laboratories, North Chicago, USA
German Research Council (DFG)-Postdoctoral-Fellow, Northwestern University
Medical School, Department of Pharmacology, Chicago, USA
German Research Council (DFG) Postdoctoral Fellow, Free University Berlin,
Institute of Pharmacology, West-Berlin, Germany
Karl-Duisberg-Fellowship, Royal Melbourne Hospital, Department of Clinical
Pharmacology, University of Melbourne, Australia
Strategic scientific leadership and management capability
Built de novo world-class inter-disciplinary, inter-institutional, academic-industry teams in both R&D
and commercialization programs by stimulating highly collaborative environments from previous
isolated entities. Outstanding communication skills, which were further sharpened during several
Harvard-based trainings focusing on team building, power of negotiation, intercultural sensitivity,
vision/mission development and implementation, finance for non-financial managers, high level of
efficient self-management (GTD and 43folders), talent identification, staff development and
appraisal, setting SMART, challenging and fulfilling goals, bringing together top-tier young and
senior research talents, high entrepreneurial success, open and constructive communication,
collaborative decision making style, stakeholder engagement, enthusiastic, inspiring and motivating
leadership style, very structured to ensure workable and synergistic (resource allocation) and
interdisciplinary collaboration.
•
•
Professor of Pharmacology for Pharmacists, Würzburg (1996-2000)
Member University Council, Würzburg (1996-1998)
2
CV – Harald HHW Schmidt, MD PhD PharmD •
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
6.
Head of Department of Pharmacology and Toxicology, Gießen (2000-2005)
Member of Faculty Academic Board, Gießen, Germany (2002-2005)
Director University Animal Facility, Gießen (2003-2005)
Member of University Ethics Committee, Gießen, Germany (2002-2004)
Head of Department of Pharmacology, Melbourne (2005-2009)
Director of Centre for Vascular Health, Melbourne (2006-2009)
Member of Faculty Board, ex officio, Melbourne (2005-2009)
Member of Monash University Academic Board, Melbourne
Member of Southern Health Therapeutics Committee, Melbourne
Member of the Monash University Inclusive Practices Workplace Equity Committee (WEC)
– Equal Opportunity Committee (2006-2007)
Chair Faculty of Medicine Theme Committee, Melbourne (2007-2009)
Monash Medical Course Managing Committee, Melbourne (2007-2009)
Monash University Biomedical Imaging Initiative, Melbourne (2007-2009)
Australian Chair Intl Core-2-Core Programme, Melbourne (2008-2009)
European Society of Cardiology Working Group Pharmacology and Therapeutics
European Vascular Biology Organisation, Council member
Head of Department of Pharmacology, Maastricht (2011-2013)
Co-Chair Personalised Medicine and Implementation Platform, Maastricht (2013-)
EU-COST Action EU-ROS, Chair (2013-14)
Cardiovascular Research Institute Maastricht, PI and member of strategic board (2010-)
Maastricht Institute of Advanced Studies, PI and member of board (2013-)
Teaching experience
•
•
•
•
•
•
•
•
7.
1987-1989: Pharmacology for Medical Students, University of Berlin
1992-2000: Pharmacology for Medical, Pharmacy Students, University of Würzburg,
establishing new course programme and curriculum; ‘Lehren und Lernen’ programme
2003: Established & developed a successful Interdisciplinary Summer Schools together
with the Law and Economics faculty
2000-2005: Pharmacology for Medical, Dentistry and Science Students, Gießen; clinicalpharmacological conferences; bed-side teaching
2005-2009: Pharmacology for Science and Medicine Students, Monash University;
curriculum development
2006-ongoing: Editor of a leading German Pharmacology text book (Estler-Schmidt),
currently licenced for eBook re-design
2007-2009: Monash University, Medicine, Medical Course Management Committee
2010-: Curriculum committees, Faculty of Medicine and Life Sciences; Honours students
committee; PreScribe online learning tool development; tutor training problem-based
learning
Major received competitive funding from national and international organizations
Led and co-led 3 multi-million research consortia, founded and led 1 successful interdisciplinary
cardiovascular biotech company, founded and led or co-led 6 interdisciplinary research centers and
consortia, all on cardiovascular & personalized medicine
• DFG SFB 535 Cardiopulmonary vascular system, Germany, 2000-2003, Co-leader
• Ditto, 2003-2006, Co-leader
• ERC Advanced Investigator Grant program, 2012-ongoing, PI
• Vasopharm Biotech, Germany, out of 3 different departments and different VCs now in
Series F, 1998-ongoing, co-founder and CEO (1998-1999)
• Centre for Vascular Health, Monash University, Melbourne; partner institutions: Melbourne
university, RMIT, Servier & SAB (approximately 130 scientists), 2007-2010, Director (20072009)
• iMed CoE, Maastricht University, the Netherlands (approximately 50 scientists), 2011ongoing, Leader
3
CV – Harald HHW Schmidt, MD PhD PharmD •
•
•
•
COST Action ENOG, European Research Council, 26 countries and partners from biotech
(approximately 120 scientists), 2011- ongoing, WG leader
COST Action EU-ROS, European Research Council, 26 countries and partners from
biotech (approximately 120 scientists), 2012- ongoing, Chair
Personalized Health innovation platform, Maastricht University, the Netherlands
(approximately 110 scientists), 2012-ongoing, co-leader
Pending: ZonMw TOP, CVON
a. Germany (past support)
Total in EUR
1986-2005
b. Australia (past and current support)
Total in AUD
2005-2012
c. Netherlands (current)
Total in EUR
8.
2011-…
€12,152,000
A$44,966,612
€4,126,000
Publications
Hirsch index h=73 (http://tinyurl.com/p4sl3vx)
m-ratio h/y post PhD=72/26=2.8
a.
Scientific publication in international journals mentioned in the Social Science Citation Index,
Science Citation Index or Arts & Humanities Citation Index
132 including
•
•
•
•
•
•
•
•
•
Schmidt HHHW, Pollock, JS, Nakane M, Gorsky LD, Förstermann U and Murad F (1991)
Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl
Acad Sci USA 88: 365-369
Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R and Schmidt HHHW (1992)
Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl
Acad Sci USA 89: 11993-11997
Schmidt HHHW, Warner TD, Ishii K, Sheng H and Murad F (1992) Insulin-secretion from
pancreatic B-cells caused by L-arginine-derived nitrogen oxides. Science 255: 721-723,
1992, Response ibid 258: 1376-1378
Schmidt HHHW, Hofmann H, Schindler U, Shutenko Z, Cunningham, D, Feelisch M (1996)
No NO from NO synthase. Proc Natl Acad Sci USA 93: 13712-13717
Zabel U, Kleinschnitz C, Oh P, Smolenski A, Nedvetsky P, Kugler P, Walter U, Schnitzer
JE, Schmidt HHHW (2002) Calcium-dependent membrane association sensitises soluble
guanylyl cyclase to NO. Nature Cell Biol 4: 307-311
Melichar, VO, Behr-Roussel, D, Zabel, U, Uttenthal, LO, Rodrigo, J, Rupin, A, Verbeuren,
TJ, Kumar, A, Schmidt, HHHW (2004) Reduced cGMP signaling associated with
neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl
Acad Sci USA, 101: 16671-16676
Dikalova A, Clempus R, Lassègue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A,
Webera DS, Weiss D, Taylor WR, Schmidt HHHW, Owens GK, Lambeth JD, Griendling
KK (2005) Nox1 overexpression potentiates angiotensin II-induced hypertension and
vascular smooth muscle hypertrophy in transgenic mice. Circulation 112 2668-2676
Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP,
Gnoth MJ, Seeger W, Grimminger F, Schermuly RT (2006) Activation of Soluble Guanylate
Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling.
Circulation 113: 286-295
Stasch JP, Nedvetsky PI, Schmidt PM, Kumar AHS, Nedvetskaya TY, Meurer S, Deile M,
Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Kemp-Harper B, Müller-Esterl
W, Schmidt HHHW (2006) Targeting the heme-oxidized nitric oxide receptor for selective
vasodilation of diseased blood vessels. J Clin Invest 116: 2552-2561
4
CV – Harald HHW Schmidt, MD PhD PharmD Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T,
Geis C, Barthel K, Schumann M, Kraft P, Herrmann A, Meuth SG, Stoll G, Meurer S,
Becker L, Gailus-Durner V, Fuchs H, Klopstock T, Hrabé de Angelis M, Jandeleit-Dahm K,
Shah AM, Weissmann N, Schmidt HHHW (2010) Post-stroke inhibition of induced NADPH
oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 8: e1000479
Weissmann N, Sydykov A, Kalwa H, Storch U, Fuchs B, Mederos y Schnitzler M, Brandes
RP, Grimminger F, Meissner M, Freichel M, Offermanns S, Veit F, Pak O, Krause K-H,
Schermuly RT, Brewer AC, Schmidt HHHW, Seeger W, Shah AM, Gudermann T, Ghofrani
HA, Dietrich A (2011) Activation of the TRPC6 channel is essential for ischemiareperfusion-induced lung edema. Nature Commun 3: 649
Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB,
Koulis C, El-Osta A, Andrews KL, Chin Dusting JP, Touyz RM, Wingler K, Cooper ME,
Schmidt HHHW, Jandeleit-Dahm KA (2013) NADPH oxidase 1 plays a key role in diabetes
mellitus-accelerated atherosclerosis. Circulation 127: 1888-1902
Kleinschnitz C, Mencl S, Kleikers PWM, Schuhmann MK, García López M, Casas Guijarro
AI, Reif A, Schmidt HHHW (2015) Technical Comment on “A Translational Paradigm for
the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic
Nonhuman Primates”. Science Translational Medicine (in press)
•
•
•
•
b.
WB/WBC: Scientific publication as a book or as a contribution to a book including
proceedings
st
Griendling KK, Krause KH, Schmidt HHHW (2004) 1 International Conference on NADPH
oxidases. BoD, Norderstedt, Germany
th
Estler J-C, Schmidt HHHW (2006) Pharmacology and Toxicology. Schattauer, 6 Edt
(Textbook, in German)
Schmidt HHHW, Hofmann F, Stasch JP. (2009) Handbook of Experimental Pharmacology
191. cGMP: generators, effectors and therapeutic implications. Preface. Handb Exp
Pharmacol. 191:v-vi
•
•
•
c.
Patents
1
2
3
4
5
6
7
8
9
10
11
Pfleiderer W, Schmidt HHHW, Henning R (1998) Tetrahydropteridine derivatives as
inhibitors of nitric oxide synthase, Germany (DE 4418097 A1951130) (GRANTED)
Pfleiderer W, Schmidt HHHW, Henning R (1998) Tetrahydropteridine derivatives as
inhibitors of nitric oxide synthase, Canada (CAN 124:76535) (GRANTED)
Pfleiderer W, Schmidt HHHW, Henning R (1998) Pteridine derivatives as inhibitors of
nitric oxide synthase, Germany (DE 4418096 A1 951130) (GRANTED)
Pfleiderer W, Schmidt HHHW, Henning R (1998) Pteridine derivatives as inhibitors of
nitric oxide synthase, Canada (CAN 124:76534) (GRANTED)
Schmidt HHHW, Zabel U, Poller W (2000) Isolierte und gereinigte humane lösliche
Guanylyl-Cyclase alpha1/beta1, Germany (DE0019837015A1) (GRANTED, nonexclusive licence to Pfizer, USA)
Schmidt HHHW, Zabel U, Poller W (2000) Isolated and purified human soluble
guanylyl cyclase alpha1/beta1 (hsgcalpha1/beta1) AU0001027400A (GRANTED)
Schmidt HHHW, Zabel U, Poller W (2000) Isolated and purified human soluble
guanylyl cyclase alpha1/beta1 (hsgcalpha1/beta1), PCT (WO020009711C1)
(GRANTED)
Schmidt HHHW, Zabel U, Poller W (2001) Isolated and purified human soluble
guanylyl cyclase alpha1/beta1 (hsgcalpha1/beta1), Europe (EP0001105503A2)
(GRANTED)
Pfleiderer W, Schmidt HHHW, Fröhlich L, Kotsonis P, Taghavi-Moghadam S (2001) Nsubstituierte 4-Aminopteridine Verfahren zu ihrere Herstellung und ihre Verwendung
als Arzneimittel, Germany (DE0019944767A1) (GRANTED)
Pfleiderer W, Schmidt HHHW, Fröhlich L, Kotsonis P, Taghavi-Moghadam S (2001) Nsubstituted 4-aminopteridines synthesis and use thereof as pharmaceutical agent,
Europe (EP009641549) (GRANTED)
Pfleiderer W, Schmidt HHHW, Fröhlich L, Kotsonis P, Taghavi-Moghadam S (2001) Nsubstituted 4-aminopteridines synthesis and use thereof as pharmaceutical agent,
USA (US10/070976) (GRANTED)
5
CV – Harald HHW Schmidt, MD PhD PharmD 12
13
14
d.
Schmidt HHHW, Zabel U, Poller W (2001) Isolated and purified human soluble
guanylyl cyclase alpha1/beta1 (hsgcalpha1/beta1), PCT (WO0200009711A3)
(GRANTED)
Tegtmeier F, Walter U, Schinzel R, Wingler K, Scheurer P, Schmidt H (2003)
Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the
inhibition of NAD(P)H oxidases and platelet activation, World WO2005/111041A1
(SUBMITTED, PUBLIC IN 2005)
Schmidt H, Wingler K, Komesker G (2004) L-Arginine containing pharmaceutical
composition, PCT (WO 2004/017955 A1) (SUBMITTED, PUBLIC IN 2004, TO
MARKET IN 2004)
Other publications
32 Reviews / Commentaries including
•
•
•
•
9.
Schmidt, HHHW, Warner, T D and Murad (1992) F Double-edged role of endogenous nitric
oxide. Lancet 339: 986
Schmidt HHHW and Walter U (1994) NO at work Cell 78 919-925 “IF=40.481” (1005)
Nedvetsky PI, Sessa WC, Schmidt HHHW (2002) There's NO binding like NOS binding:
protein-protein interactions in NO/cGMP signaling. Proc Natl Acad Sci U S A. 99: 1651016512
Nitric oxide-independent stimulators and activators of soluble guanylyl cyclase. Nature
Reviews Drug Discovery 5: 755-768
Other contributions to meetings, seminars and lectures
Prizes and distinctions
•
•
•
•
•
•
•
10.
2011: ERC Advanced Investigator
2010: Pro Scientia Prize of the Eckhart-Buddecke-Foundation to Support Basic Medical
Research, Münster
2000: German Society for Cell Biology Award for life-time achievement and subsequent
member of selection committee
2000: German Pharmaceutical Society Phoenix Prize
1999: Science4Life Prize (Germany-wide) for the best biotech business concept
1989: Postdoctoral Fellowship (DFG)
1984: Early Career Fellowship (Stifter Verband)
Other personal characteristics
Comfortable with
ambiguity and highly
matrixed organizational
structures.
In every of my teams and larger institutions I utilize and/or
introduce matrix systems both to make optimal use of
expertise,
i.e.
methodological/procedural
versus
content/strategy or breadth versus depth. I am deeply
convinced that this increases teaching and research quality
and effectiveness. However, great care has to be taken to
ensure
transparent
decision-making
and
clear
communication to ensure continuous enthusiastic
engagement of every team member and optimal
knowledge management.
Decisive, action-oriented,
motivated by results more
than process.
Both at an individual and team level results orientation is
key, allowing and stimulating risk-taking and accountability;
this is fostered by SMART joint goal setting, recognition
and clear feedback; proactive back-up planning and
double-checking approaches ensuring timely and efficient
6
CV – Harald HHW Schmidt, MD PhD PharmD achievement of goals.
Low level of ego;
motivated by the success
of my team and the
organisation rather than
advancing one’s personal
career above other
considerations.
11.
I strongly believe in team approaches; everyone needs to
have his/her clearly defined role and be equally recognized
for this. Risk taking, perseverance, questioning structures
and approaches as well as flexibility need to be
encouraged. It is important that as a team we celebrate
success and make sure that every team member sees
his/her personal goals reflected in the team and can trust
on being recognized and supported by his/her line
manager and colleagues, also with respect to personal
career objectives. Within every team, second and third line
managers are ideally multipliers of this leadership
approach and, on a daily basis, act as role models for the
team’s culture.
Community Engagement / Hobbies
Community Engagement:
• Rotary International: Incoming President, Past-Secretary, Paul Harris Fellow, RC Aachen;
past member of RC Gießen Altes Schloss and RC Melbourne
• International Soccer Referee: Street Soccer World Cup, European and National
Championchips (Germany, Netherlands, Switzerland); Referee Instructor (Germany)
• Big Issue, Melbourne
• Freundeskreis Botanischer Garten, Chair, Gießen, 2002-2005
• World Health Summit, Australien delegation co-leader, 2009
• Advisory role: State Government Victoria, Australia; Hochschulgruppe, Landtagsfraktion
der Grünen, NRW
Other:
• Contemporary Arts incl. collection, Art House Cinema, Opera
• Cycling, Fitness, Jogging
7